Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.
Roche, Zealand pact for up to $5.3B is focused on new obesity drug
Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit royalties up to high teens on net sales in the rest of the world.
So far, that hasn’t been an issue with Roche’s drug or another BTK from Novartis called remibrutinib. All four drugs are in phase 3 testing, in a closely-fought contest to bring a new oral ...
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback